Health19 hours ago
Corcept Therapeutics Achieves “Buy” Consensus Amid Analyst Adjustments
Corcept Therapeutics Incorporated (NASDAQ:CORT) has received an average consensus rating of “Buy” from five brokerage firms currently covering the stock, according to Marketbeat Ratings. Analysts have...